Equity Overview
Price & Market Data
Price: $21.40
Daily Change: -$0.20 / 0.93%
Daily Range: $20.88 - $22.32
Market Cap: $454,620,608
Daily Volume: 68,144
Performance Metrics
1 Week: -15.68%
1 Month: -11.28%
3 Months: 19.35%
6 Months: 100.9%
1 Year: 62.12%
YTD: -30.47%
Company Details
Employees: 300
Sector: Health technology
Industry: Biotechnology
Country:
Details
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.